基本信息
views: 69
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Annemieke Geluk (immunologist and chemist) studied Chemistry at the University of Leiden (Prof. Jacques van Boom) and the University of Virginia, Charlottesville, USA (Prof. Sidney Hecht). During her PhD, she specialized as an immunologist at the Department of Immunohematology and Blood Bank (Prof. Jon van Rood) at the LUMC as well as Cytel Corporation in San Diego, USA (Prof. Alessandro Sette) and received postdoctoral training at the Mayo Clinic, Rochester, MN, USA (Prof. Chella Davis).
In 1996 the Royal Dutch Academy of Sciences acknowledged her a 5-year fellowship during which she focused on the immunology of leprosy and tuberculosis (TB), particularly the identification of immunogenic antigens and biomarkers specific to these mycobacterial diseases. This includes identification of immune-, genetic, metabolic biomarkers and expanded to live Mtb challenge animal models for development of new subunit TB vaccines.
Over the past 30 years, Geluk has made important contributions to the knowledge of (T-cell) immunity against Mycobacterium leprae and M. tuberculosis. She designed and coordinated (wrt research, budget, planning) multiple large-scale, multi-center studies in e.g. Bangladesh, Brazil, Ethiopia and Nepal, and is an advisor in multiple leprosy and TB research projects abroad.
Currently, her research focusses on Global Health and One Health and is aimed at the development of novel tools and strategies to predict, diagnose, prevent and better treat leprosy and tuberculosis.
To accomplish this, she translates innovative basic research in immunology and molecular biology of mycobacterial infections to field applications using longitudinal-population studies in LMICs, but also screening of animals (red squirrels, armadillos, non-human primates) and analysis of environmental sources.
Geluk literally works from bench to bedside, and particularly committed herself to immunodiagnostics of mycobacterial diseases. This has, for example, resulted in transcriptomic signatures to predict paucibacillary leprosy, and quantitative immunodiagnostic tests for TB Triage, or diagnosis of leprosy which are currently evaluated in various trials in endemic areas.
For leprosy diagnostics, large scale production in collaboration with an FDA-approved company was initiated, allowing monitoring the effect on transmission of (post-exposure-prophylactic) interventions at population-level in endemic areas.
As witnessed by her participation in prestigious EDCTP and NIH projects, and as PI in a string of NLR/LRI projects for two decades, Geluk is a key figure valued by colleagues in international consortia for leprosy- and tuberculosis research, despite working part-time for several years (parental-leave).
Her contributions are highly respected, as evidenced by publications in leading journals such as PNAS, J. Exp. Med, iScience, EBiomedicine, J. Immunol., and Lancet Inf. Dis.
At national level, Geluk’s group provides routine (host- and pathogen based) leprosy diagnostics with service to other European countries and the Antilles.
She is co-founder of the NFU-recognized, Dutch Leprosy Expertise Center and secretary of the Q.M. Gastmann-Wichers Foundation that supports small-scale social and scientific leprosy projects.
Geluk is frequently invited as speaker, advisor on leprosy guidelines and -research projects and reviewer of project-proposals and articles. Of note is her participation in the WHO Task Force on definitions, criteria and indicators for interruption of transmission and Elimination of Leprosy that endorses the use of a quantitative and field-friendly immunodiagnostic-test for monitoring leprosy elimination as part of new leprosy health care policy.
Geluk contributes considerably to education of students Biomedical Sciences and Medicine at the LUMC, but also considers it her obligation to contribute to Global Health by educating researchers in LMICs.
Since 2005 she therefore, provides workshops on laboratory techniques and diagnostic-test performance, as well as seminars on immunology of leprosy and tuberculosis in Bangladesh, Brazil, Ethiopia, Indonesia, India, Madagascar and Nepal, resulting in essential, local capacity building.
Research Interests
Papers共 217 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Sille Pelser,Annemieke Geluk, Wynand H. P. M. Vissers, Nikki Knijn,Colette L. M. van Hees,Robert-Jan Hassing
JOURNAL OF TRAVEL MEDICINEno. 4 (2024)
One Health (2024): 100763-100763
Hana Krismawati,Sri V Muchtar,Mutia Rahardjani, Nindya N Utami, Margareta Oktaviani, Khairunnisa Puspatriani, Syamsiah, Nelly Imbiri, Dian E Hasvitasari, Dwi R Fajrianti, Nico Tarino, Fitri Wulandari,
Wellcome open research (2024): 289-289
Zijie Zhou,Anouk van Hooij, Gaby N Wassenaar, Emma Seed, Els M Verhard-Seymonsbergen,Paul L A M Corstjens,Anna L Meredith,Liam A Wilson,Elspeth M Milne,Katie M Beckmann,Annemieke Geluk
Animals : an open access journal from MDPIno. 13 (2024): 2005
M. M. Szachniewicz, M. A. Neustrup,K. E. van Meijgaarden,W. Jiskoot, A. Bouwstra,M. C. Haks,A. Geluk,T. H. M. Ottenhoff
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2024): 106730-106730
Dian E. Hasvitasari, Nelly Imbiri, Nico Tarino, Dwi R. Fajrianti, Stephen L. Walker, Fitri Wulandari,Raph L. Hamers, Nindya N. Utami,Annemieke Geluk,Marlous L. Grijsen,Duc H. Du,Hardyanto Soebono,
Wellcome Open Research (2024)
Cited0Views0Bibtex
0
0
Petra Kukkaro,Sundeep Chaitanya Vedithi,David J Blok,Wim H van Brakel,Annemieke Geluk, Aparna Srikantam,David Scollard,Linda B Adams, Mathias Duck,Sunil Anand,Andie Tucker, Israel Cruz,
Madhusmita Das, Diana David, Ilse Horo,Anouk Van Hooij, Maria Tio-Coma,Annemieke Geluk,Sundeep Chaitanya Vedithi
ANNALS OF THE RHEUMATIC DISEASESno. 2 (2023): 779-780
Load More
Author Statistics
#Papers: 219
#Citation: 6918
H-Index: 48
G-Index: 73
Sociability: 7
Diversity: 0
Activity: 2
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn